{"id":"ckd-843-dose-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Fluid retention/edema"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PPAR-gamma agonists activate peroxisome proliferator-activated receptor gamma, a nuclear receptor involved in glucose metabolism and anti-inflammatory signaling. By binding to PPAR-gamma, CKD-843 improves insulin sensitivity in peripheral tissues and reduces systemic inflammation, making it potentially useful in metabolic and inflammatory conditions. This mechanism is characteristic of the thiazolidinedione drug class.","oneSentence":"CKD-843 is a selective PPAR-gamma agonist that enhances insulin sensitivity and reduces inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:13.148Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06916793","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-04-30","conditions":"Androgenetic Alopecia","enrollment":288},{"nctId":"NCT05587699","phase":"PHASE1","title":"The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-11-15","conditions":"Alopecia","enrollment":41},{"nctId":"NCT04805606","phase":"PHASE1","title":"A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-04-30","conditions":"Alopecia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5407,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CKD-843 dose#2","genericName":"CKD-843 dose#2","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CKD-843 dose #2 is part of a clinical trial studying the pharmacokinetic/pharmacodynamic profiles and safety of CKD-843 in patients with alopecia and androgenetic alopecia. The trial involves interventions CKD-843 A, CKD-843 B, and CKD-843-R, but the specific details of CKD-843 dose #2 are not provided in the available information.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}